1 / 4

CELMoDs – A Worthy Successor to REVLIMID

Multiple myeloma is a cancer of plasma cells, and it affects approximately 138,000 people worldwide. The multiple myeloma market is dominated by several drugs, with REVLIMID being the leading therapy. However, with the entry of CELMoDs, such as iberdomide, many believe that they could be a worthy successor to REVLIMID.<br>Get an Update on CELMoD Clinical Trials for Multiple Myeloma through our blog; https://www.delveinsight.com/blog/competitive-analysis-of-celmods-and-revlimid?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

xmichael
Download Presentation

CELMoDs – A Worthy Successor to REVLIMID

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CELMoDs: The Next Step in Personalized Medicine for Multiple Myeloma What is Multiple myeloma and How is it to be treated? Multiple myeloma is a cancer of plasma cells, and it affects approximately 138,000 people worldwide. The multiple myeloma market is dominated by several drugs, with REVLIMID being the leading therapy. However, with the entry of CELMoDs, such as iberdomide, many believe that they could be a worthy successor to REVLIMID. Generic competition to REVLIMID REVLIMID, also known as lenalidomide, is one of the most widely prescribed drugs for multiple myeloma. However, the drug has faced significant competition in recent years, with the entry of generic versions in 2022. The introduction of generic REVLIMID has had a

  2. considerable impact on the multiple myeloma market, with many patients switching to cheaper alternatives. The arrival of CELMODS CELMoDs, or cereblon modulating drugs, are a new class of drugs that work in a similar way to REVLIMID. They are designed to modify the activity of cereblon, a protein that plays a crucial role in the function of the immune system. The first CELMoD to receive FDA approval was iberdomide in February 2022. Mechanistic differences between CELMODs and IMiDs IMiDs and CELMoDs share a common target, Cereblon, but CELMoDs are more selective and efficient in degrading proteins. Unlike IMiDs, which are known to have off-target effects, CELMoDs have been designed to bind selectively to Cereblon and target only the proteins involved in cancer cell growth. This selectivity is expected to translate into improved efficacy and safety. Future of CELMODs The future of CELMoDs looks promising, with several CELMoDs in the pipeline. Iberdomide, a novel CELMoD, has received FDA approval for clinical trials and has shown promising results in Phase 1 studies. This drug has shown a good safety profile and significant anti-tumor activity in patients with relapsed or refractory multiple myeloma. The drug's mechanism of action has also been found to be more potent than REVLIMID, making it a potential successor to REVLIMID. Conclusion The multiple myeloma market has seen significant advancements in the past few years, with new therapies such as CELMoDs emerging as a worthy successor to REVLIMID. These drugs have been designed to overcome the limitations of existing therapies and have shown promising results in preclinical and clinical studies. With the arrival of drugs like Iberdomide, the future of CELMoDs looks promising. However, the long-term efficacy and safety of these drugs need to be established through rigorous clinical trials. Nonetheless, CELMoDs offer hope for patients with multiple myeloma, providing new avenues for the treatment of this challenging disease. Related Reports B Cell Chronic Lymphocytic Leukemia Market DelveInsight's "B Cell Chronic Lymphocytic Leukemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Chronic Lymphocytic Leukemia, historical and forecasted epidemiology as well as the B Cell Chronic Lymphocytic Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

  3. B-Cell Lymphomas Market DelveInsight's "B-Cell Lymphomas Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Lymphomas, historical and forecasted epidemiology as well as the B-Cell Lymphomas market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Behcet’s Syndrome Market DelveInsight’s “Behcet’s Syndrome Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Behcet’s syndrome in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom. Neoantigen-based Personalized Cancer therapeutic Vaccines DelveInsight’s “Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035” report delivers an in-depth understanding of the Neoantigen based Personalized Cancer therapeutic Vaccines and the Neoantigen-based personalized cancer therapeutic vaccines emerging market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Glioblastoma Multiforme Market DelveInsight's "Glioblastoma Multiforme Market Insights, Epidemiology and Market Forecast– 2032" report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. Latest Reports By DelveInsight Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market To know more about our Consulting Services, Click here: DelveInsight Healthcare Consulting Recent Blog’s By DelveInsight: ● Insights Into The Cutaneous T-cell Lymphoma Treatment Market ● Roche’s HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape

  4. ● ● Emerging Role of Digital Health in the Field of Oncology How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape How are Technological Trends and Innovations Reshaping the Dementia Care Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market Evaluating the Key Trends and Technologies Shaping the Future of Dentistry ● ● ● ● ●

More Related